Adaptation of International Guidelines for Metastatic Colorectal Cancer: An Asian Consensus

被引：16

作者：

Cheng, Ann-Lii ^{[1
,2
]}

Li, Jin ^{[3
,4
]}

Vaid, Ashok K. ^{[5
]}

Ma, Brigette Buig Yue ^{[6
]}

Teh, Catherine ^{[7
]}

Ahn, Joong B. ^{[8
]}

Bello, Maximino ^{[9
]}

Charoentum, Chaiyut ^{[10
]}

Chen, Li-Tzong ^{[11
,12
]}

Lopes, Gilberto de Lima, Jr. ^{[13
,14
,15
]}

Ho, Gwo F. ^{[16
]}

Kong, Hwai L. ^{[17
]}

Lam, Ka O. ^{[18
]}

Liu, Tian S. ^{[19
]}

Park, Young S. ^{[20
]}

Sriuranpong, Virote ^{[21
,22
]}

Sudoyo, Aru W. ^{[23
]}

Wang, Jaw-Yuan ^{[24
,25
]}

Zhang, Jun ^{[26
]}

Zhang, Su Z. ^{[27
]}

Ciardiello, Fortunato ^{[28
]}

Koehne, Clause-Henning ^{[29
]}

Shaw, Michael ^{[30
]}

Kim, Tae Won ^{[31
]}

机构：

[1] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan

[2] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 100, Taiwan

[3] Fudan Univ, Canc Hosp, Dept Med Oncol, Shanghai 200433, Peoples R China

[4] Fudan Univ, Shanghai Canc Ctr, Dept Med Oncol, Shanghai 200433, Peoples R China

[5] Medanta Canc Inst, Gurgaon, India

[6] Chinese Univ Hong Kong, Hong Kong Canc Inst, Dept Clin Oncol, Sir YK Pao Ctr Canc, Hong Kong, Hong Kong, Peoples R China

[7] Makati Med Ctr, Liver Care Ctr, Manila, Philippines

[8] Yonsei Univ, Coll Med, Dept Internal Med, Seoul, South Korea

[9] St Lukes Med Ctr, Inst Canc, Quezon City, Philippines

[10] Chiang Mai Univ, Maharaj Nakorn Chiang Mai Hosp, Fac Med, Med Oncol Unit,Dept Med, Maung Chiang Mai Dist, Thailand

[11] Natl Hlth Res Inst, Natl Inst Canc Res, Tainan, Taiwan

[12] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Internal Med, Kaohsiung, Taiwan

[13] HCor Onco, Sao Paulo, Brazil

[14] Oncoclin Brasil, Belo Horizonte, MG, Brazil

[15] Johns Hopkins Univ, Sch Med, Baltimore, MD USA

[16] Univ Malaya, Fac Med, Kuala Lumpur, Malaysia

[17] HL Kong Med Oncol Ctr Pte Ltd, Paragon Med, Singapore, Singapore

[18] Univ Hong Kong, Queen Mary Hosp, LKS Fac Med, Dept Clin Oncol, Hong Kong, Hong Kong, Peoples R China

[19] Fudan Univ, Zhong Shan Hosp, Dept Med Oncol, Shanghai 200433, Peoples R China

[20] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Hematol Oncol, Seoul, South Korea

[21] Chulalongkorn Univ, Fac Med, Dept Med, Med Oncol Unit, Bangkok 10330, Thailand

[22] King Chulalongkorn Mem Hosp, Bangkok, Thailand

[23] Univ Indonesia, Fac Med, Div Hematol Med Oncol, Jakarta, Indonesia

[24] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Div Gastrointestinal & Gen Surg, Kaohsiung, Taiwan

[25] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Ctr Canc, Kaohsiung, Taiwan

[26] Shanghai Jiao Tong Univ, Sch Med, Rui Jin Hosp, Dept Gen Surg, Shanghai 200030, Peoples R China

[27] Zhejiang Univ, Inst Canc, Hangzhou, Zhejiang, Peoples R China

[28] Univ Naples 2, Dipartimento Med Chirurg Internist Clin & Sperime, Naples, Italy

[29] Klinikum Oldenburg, Onkol Zentrum, Oldenburg, Germany

[30] MScript Ltd, Brighton, E Sussex, England

[31] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea

来源：

CLINICAL COLORECTAL CANCER | 2014年 / 13卷 / 03期

关键词：

Asia; Chemotherapy; Epidermal growth factor receptor (EGFR)-specific monoclonal antibody; KRAS; Targeted therapy; SHORT-COURSE RADIOTHERAPY; 1ST-LINE TREATMENT; PHASE-II; RANDOMIZED-TRIAL; IRINOTECAN; OXALIPLATIN; CETUXIMAB; CAPECITABINE; FLUOROURACIL; LEUCOVORIN;

D O I：

10.1016/j.clcc.2014.06.004

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Colorectal cancer (CRC) is among the most common cancers worldwide, but marked epidemiological differences exist between Asian and non-Asian populations. Hence, a consensus meeting was held in Hong Kong in December 2012 to develop Asia-specific guidelines for the management of metastatic CRC (mCRC). A multidisciplinary expert panel, consisting of 23 participants from 10 Asian and 2 European countries, discussed current guidelines for colon or rectal cancer and developed recommendations for adapting these guidelines to Asian clinical practice. Participants agreed that mCRC management in Asia largely follows international guidelines, but they proposed a number of recommendations based on regional 'real-world' experience. In general, participants agreed that 5-fluorouracil (5-FU) infusion regimens in doublets can be substituted with UFT (capecitabine, tegafur-uracil) and Si (tegafur, 5-chloro-2,4-dihydroxypyridine and oxonic acid), and that the monoclonal antibodies cetuximab and panitumumab are recommended for KRAS wild type tumors. For KRAS mutant tumors, bevacizumab is the preferred biological therapy. FOLFOX (folinic acid, 5-FU, and oxaliplatin) is preferred for initial therapy in Asian patients. The management of mCRC is evolving, and it must be emphasized that the recommendations presented here reflect current treatment practices and thus might change as more data become available. (C) 2014 Elsevier Inc. All rights reserved.

引用

页码：145 / 155

页数：11

共 27 条

[1] Toward optimized front-line therapeutic strategies in patients with metastatic colorectal cancer-an expert review from the International Congress on Anti-Cancer Treatment (ICACT) 2009 [J].

Adam, R. ;

Haller, D. G. ;

Poston, G. ;

Raoul, J. -L. ;

Spano, J. -P. ;

Tabernero, J. ;

Van Cutsem, E. .

ANNALS OF ONCOLOGY, 2010, 21 (08) :1579-1584

[2] The Oncosurgery Approach to Managing Liver Metastases from Colorectal Cancer: A Multidisciplinary International Consensus [J].

Adam, Rene ;

De Gramont, Aimery ;

Figueras, Joan ;

Guthrie, Ashley ;

Kokudo, Norihiro ;

Kunstlinger, Francis ;

Loyer, Evelyne ;

Poston, Graeme ;

Rougier, Philippe ;

Rubbia-Brandt, Laura ;

Sobrero, Alberto ;

Tabernero, Josep ;

Teh, Catherine ;

Van Cutsem, Eric .

ONCOLOGIST, 2012, 17 (10) :1225-1239

[3]

[Anonymous], 2013, NCCN Clinical Practice Guidelines in Oncology: Survivorship

[4] Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study [J].

Bokemeyer, C. ;

Bondarenko, I. ;

Hartmann, J. T. ;

de Braud, F. ;

Schuch, G. ;

Zubel, A. ;

Celik, I. ;

Schlichting, M. ;

Koralewski, P. .

ANNALS OF ONCOLOGY, 2011, 22 (07) :1535-1546

[5] Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer [J].

Bokemeyer, Carsten ;

Bondarenko, Igor ;

Makhson, Anatoly ;

Hartmann, Joerg T. ;

Aparicio, Jorge ;

de Braud, Filippo ;

Donea, Serban ;

Ludwig, Heinz ;

Schuch, Gunter ;

Stroh, Christopher ;

Loos, Anja H. ;

Zubel, Angela ;

Koralewski, Piotr .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (05) :663-671

[6] Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer [J].

Bujko, K. ;

Nowacki, M. P. ;

Nasierowska-Guttmejer, A. ;

Michalski, W. ;

Bebenek, M. ;

Kryj, M. .

BRITISH JOURNAL OF SURGERY, 2006, 93 (10) :1215-1223

[7] Efficacy of capecitabine versus 5-fluorouracil in colorectal and gastric cancers: a meta-analysis of individual data from 6171 patients [J].

Cassidy, J. ;

Saltz, L. ;

Twelves, C. ;

Van Cutsem, E. ;

Hoff, P. ;

Kang, Y. ;

Saini, J. P. ;

Gilberg, F. ;

Cunningham, D. .

ANNALS OF ONCOLOGY, 2011, 22 (12) :2604-2609

[8] PET and PET-CT for evaluation of colorectal carcinoma [J].

Delbeke, D ;

Martin, WH .

SEMINARS IN NUCLEAR MEDICINE, 2004, 34 (03) :209-223

[9] Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer:: The Gruppo Oncologico Nord Ovest [J].

Falcone, Alfredo ;

Ricci, Sergio ;

Brunetti, Isa ;

Pfanner, Elisabetta ;

Allegrini, Giacomo ;

Barbara, Cecilia ;

Crino, Lucio ;

Benedetti, Giovanni ;

Evangelista, Walter ;

Fanchini, Laura ;

Cortesi, Enrico ;

Picone, Vincenzo ;

Vitello, Stefano ;

Chiara, Silvana ;

Granetto, Cristina ;

Porcile, Gianfranco ;

Fioretto, Luisa ;

Orlandini, Cinzia ;

Andreuccetti, Michele ;

Masi, Gianluca .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (13) :1670-1676

[10]

Ferlay J, GLOBOCAN 2008 V2 0

← 1 2 3 →